why choose us

Clinical Trials Search

Showing 12,260 of 132,366 result(s)
Biomarker Study of ATH434 in Participants With MSA

Status: Completed

Condition: Multiple System Atrophy

Interventions: ATH434 taken by mouth two times per day

Date: 2023-05-09

Beetroot Juice and Sleep

Status: Completed

Condition: Healthy

Interventions: aBRJ will consist of 70ml concentrated beetroot juice with 6.45-7.26mmol
inorganic nitrate (range for inter-batch variability) taken orally.

Date: 2023-05-09

ZYNRELEF® for Postoperative Analgesia After Laparoscopic Sleeve Gastrectomy

Status: Completed

Condition: Post Operative Pain, Acute

Interventions: ZYNRELEF® is an extended-release, fixed-ratio combination product that contains bupivacaine (a local anesthetic as the free base) and low-dose meloxic

Date: 2023-05-09

A Study to Investigate Behavioral and Other Co-Occurring Outcomes With Epidiolex as Add-On Therapy in Participants Aged 1 to 65 Years of Age With Tuberous Sclerosis Complex

Status: Completed

Condition: Tuberous Sclerosis Complex Associated Neuropsychiatric Disease

Interventions: 100 mg;ml Cannabidiol Oral solution

Date: 2023-05-09

Operant Conditioning of Sensory Brain Responses to Reduce Phantom Limb Pain in People With Limb Amputation

Status: Completed

Condition: Phantom Limb Pain After Amputation

Interventions: This is a training intervention to strengthen the weakened sensorimotor responses and reduce pain, after a limb amputation.
Non-painful periphera

Date: 2023-05-09

Project Sueño: Sleep & Understanding Early Nutrition in Obesity

Status: Completed

Condition: Infant Overweight

Interventions: See Arm description.

Date: 2023-05-09

Arginine Replacement Therapy in COVID-19

Status: Completed

Condition: COVID-19

Interventions: Arginine will be infused based on the manufacturer's instructions (R-Gene 10, Pfizer), over 30 minutes.
However, rates may be slowed to over

Date: 2023-05-09

A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis

Status: NOT_YET_RECRUITING

Condition: Relapsing-remitting Multiple Sclerosis

Interventions: Intravenous(IV) infusion

Date: 2023-05-09

A Safety and Efficacy Study of HG004 in Subjects With Leber Congenital Amaurosis

Status: NOT_YET_RECRUITING

Condition: Leber Congenital Amaurosis

Interventions: Low dose Medium dose High dose

Date: 2023-05-09